Dr. Janet Chollet has shaped a career that brings together clinical care, translational research, and the development of therapeutic programs aimed at areas of significant unmet need in women’s health. As a board-certified obstetrician–gynecologist and the Co-Founder and Chief Medical Officer of Procyrn LLC, she leads efforts to advance sustained-release biologics and reformulated antivirals. Her work focuses on maternal–fetal health, neuroinflammation, and HPV-associated cervical disease, reflecting a measured approach to translating scientific ideas into treatments that can be used safely and effectively in real clinical environments. Across more than thirty years, she has contributed to academic medicine and patient care through positions at respected institutions. Her experience includes earning three U.S. patents in drug-delivery innovation and supporting the advancement of multiple early-stage therapeutic programs. These efforts highlight her long-standing interest in developing targeted, practical solutions that align with the clinical challenges faced by patients and their providers. Her academic foundation includes a Bachelor of Science in Neuroscience, followed by a medical degree and a residency in Obstetrics and Gynecology. During residency, she developed a deeper understanding of the complexities surrounding women’s health, maternal–fetal medicine, and the broader needs of families. Those formative experiences helped shape her interest in translational work that bridges clinical insight with careful scientific development. After completing residency, she entered academic clinical practice, balancing patient care with teaching responsibilities. Serving as a staff physician and instructor strengthened her commitment to integrating frontline medical experience into the design of new therapeutic approaches. Earlier in her career, she co-founded a women’s health biotechnology company, where she contributed to the development of topical and vaginal drug-delivery systems. Her work supported the issuance of several patents and played a role in the company’s subsequent merger with a public pharmaceutical organization. In 2023, she co-founded Procyrn LLC, where she guides clinical development, regulatory strategy, and translational planning. Her programs address hypertensive disorders of pregnancy, immune-modulating approaches for ALS, and selective therapeutics for HPV-driven cervical dysplasia. She also evaluates exploratory concepts involving maternal–fetal immune stabilization and its potential relationship to early neurodevelopment. Her leadership emphasizes reproducibility, disciplined planning, and clear milestones to move each program forward effectively. Earlier in her career, she contributed to creative work in television, co-writing an episode that earned significant recognition. Outside of professional responsibilities, she values family, wellness practices, travel, and creative expression, while continuing to explore how technology may support evolving clinical workflows. Dr. Janet Chollet remains committed to advancing therapeutic solutions that translate scientific understanding into meaningful patient care.